Filtered By:
Specialty: Drugs & Pharmacology
Drug: Warfarin

This page shows you your search results in order of date. This is page number 10.

Order by Relevance | Date

Total 300 results found since Jan 2013.

Thromboembolic and hemorrhagic outcomes in the direct oral anticoagulant trials across the spectrum of kidney function.
Abstract Chronic kidney disease (CKD) is a common comorbidity among patients taking direct-acting oral anticoagulants (DOACs). Herein, we evaluate the influence of kidney function on Stroke/SEE, hemorrhage and composite endpoints (Stroke/SEE/hemorrhage/death and Stroke/SEE/death) among patients on DOACs and warfarin. Baseline kidney function was categorized as GFR≥60 (reference), 45-59 and <45ml/min/1.73m2 for participants in the RE-LY (n=18,049), ARISTOTLE (n=18,187), and ENGAGE AF (n=20,798) trials. Incidence of events was compared across GFR categories. Hazard ratios for events was estimated using Cox regr...
Source: Clinical Pharmacology and Therapeutics - December 5, 2020 Category: Drugs & Pharmacology Authors: Limdi NA, Beasley TM, Sun J, Stockbridge N, Pacanowski M, Florian J Tags: Clin Pharmacol Ther Source Type: research

The harm of anticoagulation in patients with low-risk by CHADS2 and reclassified as high-risk by CHA2DS2VASc: inferences from TRAF cohort.
CONCLUSIONS: Clinical outcomes, net clinical benefit indices are negative; rates of death and hospitalization were significantly higher for OAC in reclassified category. This emphasizes the importance of greater attention to balancing the risks and benefits of OAC in patients with low risk by CHADS2 and reclassified as high-risk by CHA2DS2VASc. PMID: 33215439 [PubMed - in process]
Source: European Review for Medical and Pharmacological Sciences - November 22, 2020 Category: Drugs & Pharmacology Tags: Eur Rev Med Pharmacol Sci Source Type: research

Direct Oral Anticoagulants Versus Warfarin in the Treatment of Left Ventricular Thrombus.
CONCLUSION AND RELEVANCE: Our data suggest that DOACs may be reasonable alternatives for treatment of LV thrombus. When added to the totality of available studies, this study demonstrates that the effectiveness of DOACs in LV thrombus remains uncertain. Randomized clinical trials are needed. PMID: 33191781 [PubMed - as supplied by publisher]
Source: The Annals of Pharmacotherapy - November 15, 2020 Category: Drugs & Pharmacology Authors: Willeford A, Zhu W, Stevens C, Thomas IC Tags: Ann Pharmacother Source Type: research

Use of Direct Oral Anticoagulants in the Treatment of Left Ventricular Thrombus: Systematic Review of Current Literature
Conclusions: The use of DOACs is a reasonable alternative to vitamin-K antagonists in the management of LVT.
Source: American Journal of Therapeutics - November 1, 2020 Category: Drugs & Pharmacology Tags: Systematic Review and Clinical Guidelines Source Type: research

Non-vitamin K antagonist oral anticoagulants for stroke prevention in atrial fibrillation: safety issues in the elderly.
Abstract INTRODUCTION: Non-vitamin K antagonist oral anticoagulants (NOACs) are increasingly used for stroke prevention in patients with atrial fibrillation (AF). Since NOACs are predominantly used in the elderly with AF at high risk for stroke and bleeding and with comorbidities requiring polypharmacy, it is important to assess their safety and efficacy in this population. AREAS COVERED: We review changes in pharmacokinetics and pharmacodynamics observed with senescence and the effect on NOACs and drug and food interactions. We also provide an update on challenges related to NOAC use in situations that incre...
Source: Pharmacological Reviews - October 27, 2020 Category: Drugs & Pharmacology Authors: Ajam T, Cumpian TL, Tilkens BL, Jahangir IA, Frost J, Ceretto C, Jahangir A Tags: Expert Rev Clin Pharmacol Source Type: research

Closure Device-Related Thrombosis After Anticoagulation With Dabigatran in Patients Undergoing Percutaneous Left Atrial Appendage Closure: Case Reports and Literature Review
We presented four rare cases of thrombosis formation on the occluder device. After the LAAC operation was successfully performed on patients, they followed a course of anticoagulation with dabigatran (110 mg b.i.d.), and device-related thrombosis (DRT) occurred as indicated by a transesophageal echocardiogram (TEE) during the follow-up period. Regressions were achieved after replacing dabigatran with rivaroxaban or warfarin for more than 1 month. No thrombosis or bleeding-related complications occurred in subsequent follow-ups.
Source: Frontiers in Pharmacology - September 7, 2020 Category: Drugs & Pharmacology Source Type: research

Appropriate Dosing Regimens of Non-Vitamin K Antagonist Oral Anticoagulants for Treatment of Patients With Non-Valvular Atrial Fibrillation: An Evidence-Based Consideration
This article summarizes the discrepancy in NOACs management with emphasis on the dosing regimens and influencing factors, such as stroke risk, age, body weight, renal function, gastrointestinal bleeding (GIB) risk, and combination of antiplatelet therapy, in order to identify individual groups with particular clinical characteristics who may obtain more benefit from a certain dosing regimen of NOACs. Determination of a particular subset of patient populations for the appropriate dose regimen of NOACs will help to achieve desired clinical outcomes. Furthermore, to compensate clinical evidence, we should place more emphasis ...
Source: Frontiers in Pharmacology - August 19, 2020 Category: Drugs & Pharmacology Source Type: research

Antithrombotic therapy for stroke prevention in patients with atrial fibrillation in Japan.
Authors: Maruhashi T, Higashi Y Abstract INTRODUCTION: Stroke remains one of the major public health problems in Japan. The number of patients with atrial fibrillation (AF) has been steadily increasing with the aging of the Japanese population. Appropriate oral antithrombotic therapy is necessary to prevent AF-related stroke and bleeding complications. AREAS COVERED: The authors summarize the Japanese guidelines for antithrombotic therapy, as well as the current status of antithrombotic therapy, and future perspectives for antithrombotic therapy for patients with AF in Japan. EXPERT OPINION: Further improve...
Source: Expert Opinion on Pharmacotherapy - August 12, 2020 Category: Drugs & Pharmacology Tags: Expert Opin Pharmacother Source Type: research

Comparative Outcomes Between Direct Oral Anticoagulants, Warfarin, and Antiplatelet Monotherapy Among Chinese Patients with Atrial Fibrillation: A Population-Based Cohort Study
ConclusionAntiplatelet prescribing and suboptimal warfarin management remain common in Chinese patients with AF at high risk of stroke. DOAC use may be associated with a lower risk of ischemic stroke and all-cause mortality when compared with antiplatelets and with a lower risk of ICH when compared with warfarin.
Source: Drug Safety - June 17, 2020 Category: Drugs & Pharmacology Source Type: research

Comparative Clinical Outcomes of Edoxaban in Adults With Nonvalvular Atrial Fibrillation
Conclusions: Edoxaban is a welcome addition to the NOAC's armamentarium. However, the comparative data with other novel NOACs are mostly nonexisting, and urgently needed for better individual patient assessment.
Source: American Journal of Therapeutics - May 1, 2020 Category: Drugs & Pharmacology Tags: Reviews Source Type: research

Comparative effectiveness and safety of oral anticoagulants for atrial fibrillation: A retrospective cohort study.
Authors: Holbrook A, Morrow R, Lee AYY, Foster G, Pullenyegum E Abstract Oral anticoagulants (OACs) are high-priority medications, frequently used with clinically important benefit and serious harm. Our objective was to compare the safety and effectiveness of direct-acting oral anticoagulants (DOACs) versus warfarin in a population where anticoagulation management and DOACs were readily available. A retrospective cohort study of all adults living in British Columbia with a diagnosis of atrial fibrillation and a first prescription for an OAC was conducted. Co-primary outcomes were ischemic stroke and systemic emboli...
Source: Journal of Population Therapeutics and Clinical Pharmacology - April 24, 2020 Category: Drugs & Pharmacology Tags: J Popul Ther Clin Pharmacol Source Type: research

Antithrombotics in intracerebral hemorrhage in the era of novel agents and antidotes: A review.
CONCLUSION: Antithrombotic therapy is of great importance when indicated, though it does not come without crucial side-effects, such as ICH. Optimal timing of withdrawal, reversal, and resumption of antithrombotic treatment should be determined by a multidisciplinary team consisting of a stroke specialist, a cardiologist, and a neurosurgeon, who will individually approach the needs and risks of each patient. PMID: 32320168 [PubMed - in process]
Source: Journal of Population Therapeutics and Clinical Pharmacology - April 24, 2020 Category: Drugs & Pharmacology Tags: J Popul Ther Clin Pharmacol Source Type: research

Risk factors for severe bleeding events during warfarin treatment: the influence of sex, age, comorbidity and co-medication
ConclusionMost of the well-established risk factors were found to be significantly associated with bleeding events in our study. We additionally found that women had a lower incidence of bleeding. Potential biases are selection effects, residual confounding and unmeasured frailty.
Source: European Journal of Clinical Pharmacology - March 27, 2020 Category: Drugs & Pharmacology Source Type: research

Apixaban safer than warfarin for patients regardless of stroke history
Apixaban is associated with less major bleeding, death and hospitalisation than warfarin, regardless of a patient ’s stroke history, a secondary analysis of the AUGUSTUS trial has indicated.
Source: The Pharmaceutical Journal - March 12, 2020 Category: Drugs & Pharmacology Source Type: research

Drug treatment strategies for osteoporosis in stroke patients.
Authors: Hsieh CY, Sung SF, Huang HK Abstract Introduction: Osteoporosis and subsequent fractures are well-recognized complications of stroke. However, drug treatment strategies for osteoporosis after stroke have been rarely discussed in the current guidelines for the management of stroke or osteoporosis.Areas covered: The authors review the epidemiology, characteristics, pathophysiology, and risk prediction of post-stroke osteoporosis and fractures. Then they provide an overview of existing evidence regarding drug treatment strategies for osteoporosis in stroke patients. They also review the effects on bone minera...
Source: Expert Opinion on Pharmacotherapy - March 11, 2020 Category: Drugs & Pharmacology Tags: Expert Opin Pharmacother Source Type: research